ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	11/30/1961
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

BCL6 (3q27) Gene Rearrangement by FISH

ARUP test code 3001311

BCL6 FISH Result	Negative Controls were run and performed as expected. This result has been reviewed and approved by Anton Rets, M.D.
Total Cell Count	126
Scoring Method	Computer Assisted
BCL6 FISH Reference Number	SE22-21983 A1
BCL6 FISH Source	Omentum

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: BCL6 (3q27) Gene Rearrangement, FISH

BCL6 fluorescence in situ hybridization (FISH) analysis is designed to detect 3q27 (BCL6) translocations regardless of rearrangement partners. Differentially labelled probes targeting the upstream (5') and downstream (3') flanking regions of the BCL6 gene were used (Agilent Technologies).

When 12 percent or more of the cells evaluated show an abnormal signal pattern, it is considered a positive result. Some signal patterns other than the classic abnormal pattern may also be present and may be considered abnormal.

BCL6 rearrangement is commonly found in diffuse large B-cell lymphomas (DLBCL) and follicular lymphomas. Results should be correlated with clinical, morphologic and immunophenotypic data. Based on the assay performance during test validation, the test is expected to detect 100 percent of BCL6 rearrangements in patients with BCL6-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

IGH-BCL2 Fusion, t(14;18) by FISH

ARUP test code 3001298

BCL2 FISH Result	Positive Controls were run and performed as expected. This result has been reviewed and approved by Anton Rets, M.D.
Total Cell Count	105
Scoring Method	Computer Assisted
BCL2 FISH Reference Number	SE22-21983 A1
BCL2 FISH Source	Omentum

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: IGH-BCL2 t(14;18), FISH

IGH-BCL2 fluorescence in situ hybridization (FISH) analysis is designed to detect the IGH-BCL2 fusion associated with t(14;18)(q32;q21). Differentially labeled fluorescent probes directed against IGH and BCL2 were used (Agilent Technologies).

Fused signals within a cell are considered abnormal signal patterns and are consistent with IGH-BCL2 fusion. If a sample contains single fused signals seen in 21 percent or more of the cells, or two or more fused signals in 6 percent or more of the cells evaluated, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of IGH-BCL2 rearrangements in patients with IGH-BCL2-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

IGH-BCL2 fusion is seen in a variety of B-cell lymphomas including follicular lymphomas, diffuse large B-cell lymphomas (DLBCL), and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

Controls performed appropriately.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Aggressive B-Cell Lymphoma Reflex Panel by FISH, Tissue

ARUP test code 3001495

MYC FISH Result	Positive LSI MYC by FISH result is positive. Testing has been reflexed to BCL2_FISH and BCL6_FISH based on client order. Controls were run and performed as expected. This result has been reviewed and approved by Anton Rets, M.D.
Total Cell Count	333
Scoring Method	Computer Assisted
MYC FISH Reference Number	SE22-21983 A1

H=High, L=Low, *=Abnormal, C=Critical

MYC FISH Source	Omentum

INTERPRETIVE INFORMATION: MYC Rearrangement, FISH

MYC fluorescence in situ hybridization (FISH) analysis is designed to detect 8q24 (MYC) translocations regardless of rearrangement partners. Differentially labeled probes targeting the upstream (5') and downstream (3') flanking regions of the MYC gene were used (Agilent Technologies).

When 12 percent or more of the cells evaluated show a classic (typical) abnormal signal pattern, it is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of MYC rearrangements in patients with MYC-rearranged lymphomas, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively.

MYC rearrangement is seen in a variety of B-cell lymphomas, including diffuse large B-cell lymphomas (DLBCL), Burkitt lymphoma, and "double hit" or "triple hit" lymphomas. Results should be correlated with clinical, morphologic, and immunophenotypic data.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin- and eosin-stained section.

The use of this assay on decalcified tissues has not been validated. Results should be interpreted with caution.

Controls performed appropriately.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
BCL2 FISH Result	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL6 FISH Result	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MYC FISH Result	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total Cell Count	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total Cell Count	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total Cell Count	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Scoring Method	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Scoring Method	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Scoring Method	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL2 FISH Reference Number	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL6 FISH Reference Number	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MYC FISH Reference Number	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL2 FISH Source	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
BCL6 FISH Source	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MYC FISH Source	22-332-147713	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical